North America and Western Europe — two wealthier regions of the world — reported the highest incidences and are projected to ...

“Our study demonstrated in a large real-world population that long-term treatment of up to 5 years with adalimumab in adult patients with psoriasis led to a sustained improvement in the practice of ...

Mumbai-based Sun Pharma has introduced its global innovative biologic Ilumya (Tildrakizumab) in India for the treatment of ...

Researchers in China report that global incidence rates of psoriasis rose slightly from 1990 to 2021 and are projected to ...

Innovent Biologics ( ($HK:1801) ) has provided an announcement. Innovent Biologics has announced that its new drug, PECONDLE® (picankibart ...

What lies beneath the surface? Ultrasound is revealing the earliest signs of psoriatic arthritis, and changing care in the ...

Background: Psoriasis is a long-term, immune-mediated inflammatory disorder of the skin, affecting about 2-3% of the global population with rising prevalence rates. Clinical practice has demonstrated ...

Patients with psoriasis who receive antibiotics may be more likely to discontinue their biologic therapy, a new study suggests. 1 In this French cohort study, the effect increased with multiple ...